| Objectives To compare efficacy and prognosis of recombinant human brain natriuretic peptide, rh BNP) or sodium nitroprusside on early acute heart failure patients.Methods The patients（294 cases） with acute heart failure were continuously collected from March 2014 to July 2015 in the first Department of Cardiology of Tangshan Gongren Hospital. Then all patients were randomly divided into the experimental group（147 cases） and the control group（147 cases）. The patients of experimental group were treated by rh-BNP on the basis of anti-heart failure treatment, and rh-BNP was intravenously injected with 0.0075μg·kg-1·min-1 last 7 days. The patients of control group were treated by sodium nitroprusside on the basis of anti-heart failure treatment, and sodium nitroprusside was intravenously injected with 2μg·kg-1·min-1 in the absence of light. The dose was adjusted based on symptoms and blood pressure. The usual dose was 3μg·kg-1·min-1, the maximum dose was 10μg·kg-1·min-1, and continuous applied of 7 days. The standard research questionnaire was strictly formulated. The detailed records of the patients consisted of the general information, the blood biochemical parameters（Nterminal probrain na-triuretic peptide, urine volume, electrolytes, renal function）, the ultrasound cardiac function tests（LVEF, SV, CI, CO）, and the blood pressure, the hospitalized time, heart failure rehospitalization rate and the number of deaths within 9 months. The database was established. SPSS21.0 statistical analysis software was used for statistical analysis. All count data were expressed as percentage（%）, and analyzed by Chi-square test. Measurement data were expressed as mean ± standard deviation（sx ±）, and analyzed by T-test. The magnitude of change in the date were used by the median（interquartile range） [M（P25-P75）], and analyzed by non-parametric test. P<0.05 indicates statistically significant difference.Results The cardiac function and urine volume were increased in two groups patients after treatment, the difference was statistically significant（P<0.05）. The change magnitude of the cardiac function and urine volume in the experimental group was significantly superior to the control group（P<0.05）. The NT-pro BNP was decreased in two groups patients after treatment, the difference was statistically significant（P<0.05）, and the change magnitude of the NT-pro BNP in the experimental group was significantly superior to the control group（P<0.05）. The blood pressure were decreased in the control group patients after treatment, the difference was statistically significant（P<0.05）, but was similar before and after treatment in the experimental group（P>0.05）. The electrolytes and renal function in two groups was similar before and after treatment（P>0.05）, and the change magnitude of the electrolytes and renal function was similar between the experimental group and the control group（P>0.05）. The hospitalized time, the heart failure rehospitalization rate and the number of deaths within 9 months in the experimental group was significantly less than the control group（P<0.05）.Conclusions 1 Compared to sodium nitroprusside, the early application of rh BNP can significantly increase the cardiac function and the 24-hour urine volume, decrease the NT-pro BNP levels, but do not affect the the blood pressure,the renal function and the electrolyte to patients with acute heart failure. 2 The early application of rhbnp can decrease the hospitalized time, the heart failure rehospitalization rate, the number of deaths within 9 months to patients with acute heart failure. |
PDF Full Text Request